The US subsidiary of South Korean biopharmaceutical company Celltrion Inc. logged record high sales in the US market last year on the back of robust sales of its self-diagnostic kit for COVID-19, officials said Monday.
The annual revenue of Celltrion USA, Inc., the wholly owned subsidiary of Celltrion, reached 84.6 billion won ($69.6 million) in 2021, sharply up from 2.36 billion won a year earlier.
The Celltrion DiaTrust COVID-19 Ag Home Test, co-developed by Humasis Co., received the US Food and Drug Administration's Emergency Use Authorization approval.
The product is also supplied through Amazon after Celltrion directly signed a contract with the world's largest online retailer.
Celltrion said Amazon directly buys the self-test kits from Celltrion USA without going through wholesalers. (Yonhap)
